5-(4-Isobutyl-phenyl)-3-(oxalyl-amino)-thiophene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-(4-Isobutyl-phenyl)-3-(oxalyl-amino)-thiophene-2-carboxylic acid
• 英文别名: 3-(Carboxyformamido)-5-(4-isobutylphenyl)thiophene-2-carboxylic acid；5-[4-(2-methylpropyl)phenyl]-3-(oxaloamino)thiophene-2-carboxylic acid
• 化学式: C₁₇H₁₇NO₅S
• 分子量: 347.392
• InChiKey: CBJMZUHIPHEMBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氨基-5-(4-异丁基苯基)噻吩-2-羧酸甲酯 在 sodium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 20.0h， 生成 5-(4-Isobutyl-phenyl)-3-(oxalyl-amino)-thiophene-2-carboxylic acid
  参考文献：
  名称：

  Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

  摘要：

  Reversible phosphorylation and dephosphorylation of key proteins on tyrosine residues are important parts of intracellular signaling triggered by hormones and other agents. Recent knock-out studies in mice have identified PTP1B as a potential target for the treatment of diabetes and obesity. As a consequence, a number of academic and industrial groups are aggressively pursuing the development of selective PTP1B inhibitors. In addition, other protein-tyrosine phosphatases (PTPs) appear to be critically involved in major diseases such as cancer and autoimmunity. Given the diversity of PTPs and their potential as drug targets in different diseases, we have taken a broad approach to develop active site-directed selective inhibitors of specific members of this family of enzymes. Using a high throughput screening, we have previously identified 2-(oxalylamino)benzoic acid 3a as a relatively weak but classical competitive inhibitor of several PTPs.(4) On the basis of our early studies, indicating that 3a might be used as a starting point for the synthesis of selective PTP inhibitors, we now present our efforts in expansion of this concept and provide here a number of new chemical scaffolds for the development of inhibitors of different members of the PTP family. Although the core structure of these inhibitors is charged, good oral bioavailability has been observed in rat for some compounds. Furthermore, we have observed enhancement of 2-deoxy-glucose accumulation in C2C12 cells with prodrug analogues.

  DOI：

  10.1021/jm0209026

文献信息

• MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES)
  申请人：——

  公开号：US20020002199A1

  公开（公告）日：2002-01-03

  The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

  本发明提供了新型化合物、新型组合物、它们的使用方法以及制备方法，其中这些化合物是药理学上有用的蛋白酪氨酸磷酸酶（PTPase's）抑制剂，例如PTP1B、CD45、SHP-1、SHP-2、PTP&agr;、LAR和HePTP等。这些化合物在治疗I型糖尿病、II型糖尿病、糖耐量受损、胰岛素抵抗、肥胖症、免疫功能障碍（包括凝血系统功能失调的自身免疫性疾病）、过敏性疾病（包括哮喘）、骨质疏松症、增生性疾病（包括癌症和牛皮癣）、合成或效应减少或增加的生长激素相关疾病、合成或反应减少或增加的调节生长激素释放或反应的激素或细胞因子相关疾病、包括阿尔茨海默病和精神分裂症在内的脑部疾病以及传染病治疗中有用。
• Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
  申请人：Jeppesen Lone

  公开号：US20050119332A1

  公开（公告）日：2005-06-02

  The present invention provides novel compounds of formula 1a, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

  本发明提供了1a式新化合物、新组合物、其使用方法和制备方法，其中这些化合物是药理学上有用的蛋白酪氨酸磷酸酶（PTPase's）抑制剂，如PTP1B、CD45、SHP-1、SHP-2、PTPα、LAR和HePTP等。这些化合物在治疗I型糖尿病、II型糖尿病、受损的葡萄糖耐受性、胰岛素抵抗、肥胖症、免疫功能障碍，包括凝血系统功能障碍的自身免疫性疾病、过敏性疾病，包括哮喘、骨质疏松症，增生性疾病，包括癌症和银屑病，合成或效果降低或增加的生长激素的疾病，合成调节释放或响应生长激素的激素或细胞因子的疾病，包括阿尔茨海默病和精神分裂症的大脑疾病，以及传染病方面具有用处。
• Modulators of protein tyrosine phosphatases (PTPases)
  申请人：——

  公开号：US20020165398A1

  公开（公告）日：2002-11-07

  The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimers disease and schizophrenia, and infectious diseases.

  本发明提供了新型化合物、新型组合物、它们的使用方法和制造方法，其中这些化合物是药理学上有用的蛋白酪氨酸磷酸酶（PTPase's）抑制剂，如PTP1B、CD45、SHP-1、SHP-2、PTPα、LAR和HePTP等。这些化合物在治疗I型糖尿病、II型糖尿病、糖耐量受损、胰岛素抵抗、肥胖、免疫功能障碍（包括凝血系统功能障碍的自身免疫疾病）、过敏性疾病（包括哮喘）、骨质疏松症、增生性疾病（包括癌症和银屑病）、合成生长激素的减少或增加、调节生长激素释放或响应的激素或细胞因子合成减少或增加的疾病以及包括阿尔茨海默病和精神分裂症在内的脑部疾病和传染性疾病的治疗中是有用的。
• Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B
  作者：Henrik Sune Andersen、Ole H. Olsen、Lars F. Iversen、Anette L. P. Sørensen、Steen B. Mortensen、Michael S. Christensen、Sven Branner、Thomas K. Hansen、Jesper F. Lau、Lone Jeppesen、Edmond J. Moran、Jing Su、Farid Bakir、Luke Judge、Manou Shahbaz、Tassie Collins、Todd Vo、Michael J. Newman、William C. Ripka、Niels Peter H. Møller

  DOI：10.1021/jm0209026

  日期：2002.9.1

  Reversible phosphorylation and dephosphorylation of key proteins on tyrosine residues are important parts of intracellular signaling triggered by hormones and other agents. Recent knock-out studies in mice have identified PTP1B as a potential target for the treatment of diabetes and obesity. As a consequence, a number of academic and industrial groups are aggressively pursuing the development of selective PTP1B inhibitors. In addition, other protein-tyrosine phosphatases (PTPs) appear to be critically involved in major diseases such as cancer and autoimmunity. Given the diversity of PTPs and their potential as drug targets in different diseases, we have taken a broad approach to develop active site-directed selective inhibitors of specific members of this family of enzymes. Using a high throughput screening, we have previously identified 2-(oxalylamino)benzoic acid 3a as a relatively weak but classical competitive inhibitor of several PTPs.(4) On the basis of our early studies, indicating that 3a might be used as a starting point for the synthesis of selective PTP inhibitors, we now present our efforts in expansion of this concept and provide here a number of new chemical scaffolds for the development of inhibitors of different members of the PTP family. Although the core structure of these inhibitors is charged, good oral bioavailability has been observed in rat for some compounds. Furthermore, we have observed enhancement of 2-deoxy-glucose accumulation in C2C12 cells with prodrug analogues.